Table 2.
Clinical parameters of patients, (N = 14) at baseline (W0) and after EEN treatment (W8)
| W0, median (IQR) | W8, median (IQR) | p value | |
|---|---|---|---|
| Weight, kg | 64.9 (57.9–83.8) | 63.6 (58.6–78.4) | 0.01 |
| BMI, kg/m2 | 23.7 (21.5–26.3) | 23.3 (20.7–25.2) | 0.01 |
| CDAI | 137.5 (100.8–176.0) | 53.5 (35.3–76.5) | <0.01 |
| HBI | 4 (2.8–6.0) | 1 (0.0–2.0) | <0.01 |
| Cr, g/L | 1.0 (0.4–2.4) | 2.2 (1.1–3.1) | NS |
| IGF-1, µg/L | 156.0 (138.8–174.0) | 180.0 (154.5–225.3) | 0.01 |
| FC, µg/g | 895.0 (225.0–1,496) | 557.5 (161.5–1,353.0) | NS |
| CRPa, mg/L | 14.0 (7.5–23.0) | 11.0 (6.0–19.5) | NS |
| ESRa, mm/h | 7.0 (3.5–24.5) | 3.0 (3.0–10.0) | NS |
EEN, exclusive enteral nutrition; FC, faecal calprotectin; CDAI, Crohn's Disease Activity Index; HBI, Harvey-Bradshaw Index; IQR, interquartile range; IGF-1, insulin-like growth factor 1; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; N, sample size; NS, not statistically significant.
a
Sample size is 13 patients.